Cell Reports (Aug 2013)

RIP3 Inhibits Inflammatory Hepatocarcinogenesis but Promotes Cholestasis by Controlling Caspase-8- and JNK-Dependent Compensatory Cell Proliferation

  • Mihael Vucur,
  • Florian Reisinger,
  • Jérémie Gautheron,
  • Joern Janssen,
  • Christoph Roderburg,
  • David Vargas Cardenas,
  • Karina Kreggenwinkel,
  • Christiane Koppe,
  • Linda Hammerich,
  • Razq Hakem,
  • Kristian Unger,
  • Achim Weber,
  • Nikolaus Gassler,
  • Mark Luedde,
  • Norbert Frey,
  • Ulf Peter Neumann,
  • Frank Tacke,
  • Christian Trautwein,
  • Mathias Heikenwalder,
  • Tom Luedde

DOI
https://doi.org/10.1016/j.celrep.2013.07.035
Journal volume & issue
Vol. 4, no. 4
pp. 776 – 790

Abstract

Read online

For years, the term “apoptosis” was used synonymously with programmed cell death. However, it was recently discovered that receptor interacting protein 3 (RIP3)-dependent “necroptosis” represents an alternative programmed cell death pathway activated in many inflamed tissues. Here, we show in a genetic model of chronic hepatic inflammation that activation of RIP3 limits immune responses and compensatory proliferation of liver parenchymal cells (LPC) by inhibiting Caspase-8-dependent activation of Jun-(N)-terminal kinase in LPC and nonparenchymal liver cells. In this way, RIP3 inhibits intrahepatic tumor growth and impedes the Caspase-8-dependent establishment of specific chromosomal aberrations that mediate resistance to tumor-necrosis-factor-induced apoptosis and underlie hepatocarcinogenesis. Moreover, RIP3 promotes the development of jaundice and cholestasis, because its activation suppresses compensatory proliferation of cholangiocytes and hepatic stem cells. These findings demonstrate a function of RIP3 in regulating carcinogenesis and cholestasis. Controlling RIP3 or Caspase-8 might represent a chemopreventive or therapeutic strategy against hepatocellular carcinoma and biliary disease.